COVID-19 VACCINE
Posted On May 31, 2021
Pfizer-BioNTech
- Spike protein
- IM 2 doses 3 weeks apart
- Efficacy: 95% efficacy in preventing symptomatic COVID-19 7 days after receiving 2nd dose.
- Duration of protection: unknown
- Side effects:
- 65% injection site pain, less common redness, swelling
- 29% fatigue, 25% headache, 17% muscle pain after first dose. Even more frequent after second dose. More common in youger individual.
- Anaphylaxis post injection: 5 per million, 90% occurred within 30 minutes.
- After 98 million doses: no thrombocytopenia, no central venous sinus thrombosis.
Moderna
- mRNA
- Gives 2 doses IM 28 days apart
- Efficacy: 94% efficacy in preventing symptomatic COVID-19 14 days after 2nd dose.
- Side Effects
- 70 to 80% injection site pain, rednaa or swelling
- Fatigue, headache, myalgia 20-30% after first dose, 50-60% after second dose.
- After 2nd dose: fever chills in 40%
- Anaphylaxis: 2,8 events per million doses.
Oxford-AstrZeneca
- Adenovirus vector
- Given 2 doses IM 8 to 12 weeks apart
- Efficacy: 70.4% efficacy in preventing symptomatic covid-19 infection 14 days after second dose.
- Side effects: headache, fatigue, fever. Severe up to 8%
- 2 cases of transverse myelitis
- After 34 million recipient: 169 cases of cerebral venous thrombosis, 53 cases of splanchnic vein thrombosis, most also had thrombocytopenia. Most occur within 14 days after first dose, in female under 60 years old